Literature DB >> 2845899

Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.

M A Jacobson1, J Mills, J Rush, J J O'Donnell, R G Miller, C Greco, M F Gonzales.   

Abstract

We report the first published case (to our knowledge) of histopathologically documented acquired immunodeficiency syndrome-related cytomegalovirus (CMV) myelitis in which antiviral drug therapy was administered. Despite sensitivity of the patient's CMV isolate to therapy with both ganciclovir and foscarnet, use of neither of these agents halted progression of central nervous system CMV disease. Higher doses of these drugs or combination therapy may be required to treat acquired immunodeficiency syndrome-related CMV myelitis effectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845899     DOI: 10.1001/archneur.1988.00520340044009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  6 in total

1.  Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients.

Authors:  R F Miller; J D Fox; P Thomas; J C Waite; Y Sharvell; B G Gazzard; M J Harrison; N S Brink
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 2.  Cytomegalovirus polyradiculopathy treated successfully with foscarnet.

Authors:  I Corral; C Quereda; J Cobo; J L Casado; A Guerrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

Review 3.  Combined HIV-CMV encephalitis presenting with brainstem signs.

Authors:  G N Fuller; R J Guiloff; F Scaravilli; J N Harcourt-Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

Review 4.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

5.  Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples.

Authors:  D Michel; E Marre; W Hampl; J Roczkos; S Müller; B Hertenstein; P Kern; B Heymer; B Salzberger; K Arasteh
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

6.  Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma.

Authors:  Barbara Ricci; Thomas O Millner; Nicola Pomella; Xinyu Zhang; Loredana Guglielmi; Sara Badodi; Dario Ceric; Carolina Gemma; Erica Cognolato; Ying Zhang; Sebastian Brandner; Michael R Barnes; Silvia Marino
Journal:  Oncogene       Date:  2020-01-27       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.